Wellington Management Group
RXRX icon

Wellington Management Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Wellington Management Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$663K Buy
180,598
+29,179
+19% +$97.1K ﹤0.01% 1804
2026
Q1 		$465K Sell
151,419
-1,197
-0.8% -$4.63K ﹤0.01% 1781
2025
Q4 		$624K Sell
152,616
-661
-0.4% -$3.27K ﹤0.01% 1792
2025
Q3 		$748K Buy
153,277
+58,295
+61% +$306K ﹤0.01% 1830
2025
Q2 		$481K Sell
94,982
-12,494
-12% -$61.4K ﹤0.01% 1826
2025
Q1 		$569K Sell
107,476
-7,469
-6% -$54.5K ﹤0.01% 1805
2024
Q4 		$777K Buy
114,945
+9,927
+9% +$66.7K ﹤0.01% 1766
2024
Q3 		$692K Buy
+105,018
New +$753K ﹤0.01% 1771

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wellington Management Group's RXRX Position: Q2 2026 in Review

Wellington Management Group increased its Recursion Pharmaceuticals (RXRX) stake by 19% in Q2 2026, buying an estimated $97.1K and bringing the position to 180,598 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Wellington Management Group first reported a position in RXRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $777K in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Wellington Management Group held 180,598 shares of Recursion Pharmaceuticals worth $663K as of Q2 2026.
  • Wellington Management Group bought 29,179 Recursion Pharmaceuticals shares in Q2 2026, an estimated $97.1K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1804 holding.
  • Wellington Management Group first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Wellington Management Group's Recursion Pharmaceuticals position peaked at $777K in Q4 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.